Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.36 |
| ▸ | NR1H4 | Q96RI1 | 8/20 | 0.34 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.34 |
| ▸ | SYK | P43405 | 1/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.33 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.32 |
| ▸ | PLAU | P00749 | 1/20 | 0.32 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.32 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29508504 | 1.00 | PDPK1 (0.36) | PDPK1NR1H4GRM4SYKNR1H2 | |
| SCHEMBL29649948 | 1.00 | PDPK1 (0.36) | PDPK1NR1H4GRM4SYKNR1H2 | |
| SCHEMBL23012937 | 0.94 | NR1H4 (0.35) | PDPK1NR1H4GRM4SYKNR1H2 | |
| SCHEMBL27673955 | 0.89 | NR1H4 (0.34) | NR1H4GRM4NR1H2SSTR4PLAU | |
| SCHEMBL2857004 | 0.86 | NR1H4 (0.33) | NR1H4GRM4NR1H2SSTR4PLAU | |
| SCHEMBL29733555 | 0.86 | AURKA (0.33) | — | |
| SCHEMBL8233620 | 0.85 | GABRG2 (0.39) | PDPK1NR1H4GRM4SYKSSTR4 | |
| SCHEMBL22277233 | 0.84 | NR1H4 (0.40) | PDPK1NR1H4GRM2 | |
| SCHEMBL17221287 | 0.84 | ROCK1 (0.47) | PDPK1NR1H4NR1H2GRM2 | |
| SCHEMBL29481424 | 0.84 | ROCK1 (0.47) | PDPK1NR1H4NR1H2GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021032934-A1 | ENZYME INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2021-02-25 | — | — | WO | disclosed |
| EP-2934536-B1 | FACTOR IXa INHIBITORS | MERCK SHARP & DOHME (US) | 2017-09-27 | — | — | EP | disclosed |
| US-9695198-B2 | Factor IXa inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-07-04 | — | — | US | disclosed |
| US-20150368269-A1 | Factor IXa Inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-12-24 | — | — | US | disclosed |
| EP-2373634-B1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | MOCHIDA PHARM CO LTD (JP) | 2015-11-11 | — | — | EP | disclosed |
| US-9174974-B2 | Macrocyclic factor VIIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-11-03 | — | — | US | disclosed |
| US-9174974-B2 | Macrocyclic factor VIIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-11-03 | — | — | US | disclosed |
| EP-2934536-A1 | FACTOR IXa INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2015-10-28 | — | — | EP | disclosed |
| US-9161924-B2 | Factor IXa inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-10-20 | — | — | US | disclosed |
| US-9161924-B2 | Factor IXa inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-10-20 | — | — | US | disclosed |
| US-20070208054-A1 | MACROCYCLIC FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | BRISTOL-MYERS SQUIBB COMPANY | 2007-09-06 | — | — | US | disclosed |
| EP-1828152-A2 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF FACTOR VIIA | Bristol-Myers Squibb Company (US) | 2007-09-05 | — | — | EP | disclosed |
| WO-2007076431-A1 | MACROCYCLIC FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-07-05 | — | — | WO | disclosed |
| WO-2007002313-A2 | PHENYLGLYCINAMIDE AND PYRIDYLGLYCINAMIDE DERIVATIVES USEFUL AS ANTICOAGULANTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-01-04 | — | — | WO | disclosed |
| WO-2007002313-A2 | PHENYLGLYCINAMIDE AND PYRIDYLGLYCINAMIDE DERIVATIVES USEFUL AS ANTICOAGULANTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-01-04 | — | — | WO | disclosed |
| US-20070003539-A1 | Phenylglycinamide and pyridylglycinamide derivatives useful as anticoagulants | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-01-04 | — | — | US | disclosed |
| US-20070003539-A1 | Phenylglycinamide and pyridylglycinamide derivatives useful as anticoagulants | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-01-04 | — | — | US | disclosed |
| US-20060211720-A1 | Heterocyclic compounds as inhibitors of factor VIIa | BRISTOL-MYERS SQUIBB COMPANY | 2006-09-21 | — | — | US | disclosed |
| WO-2006076246-A2 | PHENYLGLYCINAMIDE DERIVATIVES USEFUL AS ANTICOAGULANTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-07-20 | — | — | WO | disclosed |
| WO-2006062972-A2 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF FACTOR VIIA | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070003539-A1 | Phenylglycinamide and pyridylglycinamide derivatives useful as anticoagulants | F12, F11, F7 | PDPK1 4288/4885NR1H4 1443/4885GRM4 2470/4885 |
| US-20060211720-A1 | Heterocyclic compounds as inhibitors of factor VIIa | TFPI, F7, HABP2 | PDPK1 1351/4885NR1H4 3676/4885GRM4 4867/4885 |
| US-20070208054-A1 | MACROCYCLIC FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | F12, F7, F2 | PDPK1 4524/4885NR1H4 1588/4885GRM4 4601/4885 |
| US-20150368269-A1 | Factor IXa Inhibitors | F9, TFPI, F13B | PDPK1 3677/4885NR1H4 1539/4885GRM4 4880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.